



Healing today. Curing tomorrow.

SANUWAVE Health, Inc.

Barry Jenkins, CFO
Bernie Laurel, VP of Sales and Marketing
678-578-0103
investorrelations@sanuwave.com

LHA

Anne Marie Fields (Investors)
212-838-3777
afields@lhai.com
Mackenzie Mills (Media)
212-838-3777
mmills@lhai.com

FOR IMMEDIATE RELEASE

**SANUWAVE ISSUED U.S. PATENT FOR A NEW METHOD TO PRODUCE
ACOUSTIC SHOCK WAVES UTILIZING PRESSURIZED FLUID**

ALPHARETTA, GA, January 17, 2012 – SANUWAVE Health, Inc. (OTCBB: SNWV) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company patent number 8,092,401, titled “Method and Apparatus for Producing Shock Waves for Medical Applications.” The patent has a term extending to February 2027 and relates to a new method of producing shock waves utilizing a mechanically pressurized fluid.

In conventional methods to produce an acoustic shock wave, the acoustic wave is triggered by an electrical impulse. By contrast, the novel method presented in this patent is mechanical and comprises oscillating high pressure generated in the encapsulated fluid within the treatment applicator, which is used to produce focused acoustic shock waves. This innovation may create efficiencies in design, manufacture and usability of the Company’s Pulsed Acoustic Cellular Expression (PACE[®]) technology and allows for unique device configurations and clinical applications that were not previously possible.

“We are pleased to be awarded this new patent as it has potential to be a significant asset in our product development efforts,” stated Christopher M. Cashman, President and CEO of SANUWAVE. “This method of producing acoustic shock waves is different from the electrohydraulic method we use in our current products, and it could give rise to new clinical indications and alternative regulatory pathways for future product offerings.”

About PACE

PACE, defined as Pulsed Acoustic Cellular Expression, delivers high-energy acoustic pressure waves in the shock wave spectrum to produce compressive and tensile stresses on cells and tissue structures which are designed to promote angiogenic and positive inflammatory responses, and quickly initiate the healing cascade. This is thought to result in microcirculatory improvement, including increased perfusion and blood vessel widening (arteriogenesis), the production of angiogenic growth factors, enhanced new blood vessel formation (angiogenesis) and the subsequent regeneration of tissue such as skin, musculoskeletal and vascular structures. PACE procedures trigger the initiation of an accelerated inflammatory response that speeds wounds into proliferation phases of healing and subsequently returns a chronic condition to an acute condition to help reinitiate the body’s own healing response.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic

responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. SANUWAVE intends to apply its PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE[®], is CE marked for treatment of the skin and subcutaneous soft tissue and recently completed its pivotal Phase III, Investigational Device Exemption (IDE) clinical trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron[®] device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron, Evotron[™] and orthoPACE[®] devices in Europe.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
